New findings on transcription regulation across different HIV-1 subtypes

AIDS Reviews

Volumn 8, Issue 1, 2006, Pages 9-16

  de Arellano, Eva Ramírez ^b   Soriano, Vincent ^b   Alcami, José ^a   Holguín, África ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HIV 1; Long terminal repeat; LTR; Subtypes; Transcription

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ANTIRETROVIRUS AGENT; CELL PROTEIN; FLAVONOID; HISTONE DEACETYLASE INHIBITOR; ISOQUINOLINE; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

ASSAY; CLADISTICS; DISEASE COURSE; EPIDEMIC; EUKARYOTE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LONG TERMINAL REPEAT; NONHUMAN; PROTEIN ANALYSIS; PROVIRUS; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS RECOMBINANT; VIRUS TRANSCRIPTION; VIRUS TYPING;

ANTI-HIV AGENTS; GENE EXPRESSION REGULATION, VIRAL; HIV ENHANCER; HIV-1; HUMANS; TERMINAL REPEAT SEQUENCES;

EID: 33646818955     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Pereira L, Bentley K, Peeters A, Churchill M, Deacon N. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res 1999;28:663-8.
2. Krebs F, Hogan T, Quiterio S, Gartner S, Wigdahl B. Lentiviral LTR-directed expression, sequence variation, and disease pathogenesis. Los Alamos 2001:29-70.
3. Brigati C, Giacca M, Albini A, et al: HIV Tat, its targets and the control of viral gene expression. FEMS Microbiol Letters 2003; 220:57-65.
4. Masanori B. Inhibitors of HIV-1 gene expression and transcription. Curr Top Med Chem 2004;4:871-82.
5. Rohr O, Marban C, Aunis D, Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leuk Biol 2003; 74:736-49.
6. Vant Lint C, Ann Amella C, Emiliani S, et al. Transcription factor binding sites downstream of the HIV-1 transcription start site are important for virus infectivity. J Virol 1997;71:6113-27.
7. El Kharroubi A, Martin M. Cis-acting sequences located downstream of the HIV-1 promoter affect its chromatin structure and transcriptional activity. Mol Cell Biol 1996;16:2958-66.
8. Peeters M, Toure-Kane C, Nkengasong J. Genetic diversity of HIV-1 in Africa: impact of diagnosis, treatment, vaccine development and trials. AIDS 2003;17:2547-60.
9. Montano M, Novitsky V, Blackard J, et al. Divergent transcriptional regulation among expanding HIV-1 subtypes. J Virol 1997; 71:8657-65.
10. Montano M, Nixon C, Essex M. Dysregulation through the NF-kB enhancer and TATA box of the HIV-1 subtype E promoter. J Virol 1998;72:8446-52.
11. Naghavi M, Schwartz S, Sönnerborg A, Vahlne A. LTR promoter/enhancer activity of different subtypes of HIV-1. AIDS Res Hum Retroviruses 1999;15:1293-303.
12. De Baar M, De Ronde A, Berkhout B, et al. Subtype-specific sequence variation of the HIV-1 type 1 LTR and primer-binding site. AIDS Res Hum Retroviruses 2000;16:499-504.
13. Jeeninga R, Hoogenkamp M, Armand-Ugon M, et al. Functional differences between the LTR transcriptional promoters of HIV-1 subtypes A through G. J Virol 2000;74:3740-51.
14. Roof P, Ricci M, Genin P, et al. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kB and the Tat transactivator. Virology 2002;296:77-83.
15. Ramirez de Arellano E, Soriano V, Holguín A. Genetic analysis of regulatory, promoter and Tar regions of LTR sequences belonging to HIV-1 non-B subtypes. AIDS Res Human Retroviruses 2005; 21:949-54.
16. Jones K, Kadonaga J, Luciw P, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, SP1. Science 1986;232:755-9.
17. Koken S, Van Wamel J, Goudsmit J, Berkhout B, Geelen J. Natural variants of the HIV-1 LTR: analysis of promoters with duplicated DNA regulatory motifs. Virol 1992;191:968-72.
18. Michael N, D'Arcy L, Ehrenberg P, Redfield R. Naturally occurring genotypes of the HIV-1 LTR display a wide range of basal and Tat-induced transcriptional activities. J Virol 1994;68:3163-74.
19. Rodenburg M, Li Y, Gao F, et al. Near full-length clones and reference sequence for subtype C isolates of HIV-1 from three different continents. AIDS Res Human Retroviruses 2001;17:161-8.
20. Rohr O, Sawaya B, Schaeffer E, et al. Dopamine stimulates expression of HIV-1 via NF-kB in cells of the immune system. Nucleic Acids Res 1999;27:3291-9.
21. Verhoef K, Sanders W, Berkhout B, et al. Evolution of the HIV-1 LTR promoter by conversion of an NF-kB enhancer element into a GABP binding sites. J Virol 1999;73:1331-40.
22. Rosen C, Sodroski J, Haseltine W. The location of cis-acting regulatory sequences in the human T-cell lymphotropic virus type III (HTLV-III/LAV) LTR. Cell 1985;41:813-23.
23. Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 1992;6:347-63.
24. Sawadogo M, Roeder G. DNA-binding specificity of USF, a human gene-specificity transcription factor required for maximum expression of the major late promoter of adenovirus. In DNA Tumor Viruses: Control of Gene Expression and Replication. Cancer Cells 1985;4:147-54.
25. Naghavi M, Estable M, Schwartz S, Roeder R, Vahlne A. Upstream stimulating factor effects HIV-1 LTR-directed transcription in a cell-specific manner, independently of the HIV-1 subtype and the core-negative regulatory element. J Gen Virol 2001;82:547-59.
26. Canonne-Hergaux F, Aunis D, Schaeffer E. Interactions of the transcription factor AP-1 with the LTR of different HIV-1 strains in Jurkat, glial and neuronal cells. J Virol 1995;69:6634-42.
27. Varin A, Manna S, Aggarwal B, et al. Exogenous Nef protein activates NF-kB, AP-1 and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem 2003;278:2219-27.
28. Koken S, van Wamel J, Goudsmit J, Berkhout B, Geelen J. Natural variants of the HIV-1 LTR: analysis of promoters with duplicated DNA regulatory motifs. Virology 1992;191:968-72.
29. Koken S, van Wamel J, Goudsmit J, Berkhout B, Geelen J. Functional analysis of the ACTGCTGA sequence motif in the HIV type 1 LTR promoter. J Biomed Sci 1994;1:83-92.
30. Zhang L, Huang Y, Yuan H et al. Identification of a replication-competent pathogenic HIV-1 with duplication in the TCF-1 alpha region but lacking NF-κB binding sites. J Virol 1997; 71:1651-6.
31. Estable M, Bell B, Hirst M, Sadowski I. Naturally occurring HIV-1 LTR have a frequently observed duplication that binds RBF-2 and represses transcription. J Virol 1998;72:6465-74.
32. Kurosu T, Mukai T, Komoto S, et al. HIV-1 subtype C exhibits higher transactivation activity of Tat than subtypes B and E. Microbiol Immunol 2002;46:787-99.
33. Daclemans D, Vandamme A, De Clerq E. HIV-1 gene regulation as a target for antiviral chemotherapy 1999;10:1-14.
34. Masanori B. Inhibitors of HIV-1 gene expression and transcription. Curr Topics Med Chem 2004;4:871-82.
35. Reynolds L, Ullman C, Choo Y. Repression of the HIV-1 5′ LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. Proc Natl Acad Sci USA 2003; 100:1615-20.
36. O'Brien W, Summer-Smith M, Chen Y, et al. Anti-HIV-1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol 1996;70:2825-31.
37. Hamy F, Felder R, Klimkait T, et al. An inhibitor of the TAt/TAR interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997;94:3548-53.
38. Daelemans D, Schols D, Vandamme A, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of HIV-1 replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000; 57:116-24.
39. Mancebo Y, Lee G, Flores O, et al. PTEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 1997;11:2633-44.
40. Kulkosky J, Culnan D, Pomerantz R, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001;98:3006-15.
41. Brooks D, Hamer D, Zack J, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003;19:413-23.
42. Rullas J, Bermejo M, Alcamí J, et al. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood. Antivir Ther 2005;9:397-406.
43. Lehrman G, Hogue L, Margolis D, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005;366: 549-55